Skip to main content
OpenTrials
Completed

NCT Number: NCT05196386

Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction.

The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.

The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-cancerous Pain Opioid Use

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rouen University Hospital

Rouen, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 and < 75 years old when entering the rheumatology department
  • Hospitalization in the rheumatology department
  • Patient with acute non-traumatic musculoskeletal disease
  • Patient not taking grade III opioid treatment
  • Patient affiliated to a social security scheme
  • Patient having read and understood the information letter and signed the consent form
  • Patient present on a day which the pharmacy intern is present

Exclusion criteria

  • Presence of cancer, fibromyalgia, already diagnosed at inclusion
  • Patient does not understand French
  • Patient with Current or past opioid addiction
  • Person deprived of liberty by administrative or judicial decision

Treatment and study plan

Admission conciliation interview

Behavioral

Previous treatment conciliation at hospital admission

Discharge conciliation interview

Behavioral

Allocated treatment during hospital stay

Targeted pharmaceutical interview

Behavioral

Specific information about treatment delivered by pharmacist

Primary outcomes

  1. Total duration of opioid treatment

    Time frame: 6 months

Secondary outcomes

  1. Rate of patients exceeding 28 days of cumulative duration of treatment

    Time frame: 6 months

  2. Rate of patients exceeding 90 days of cumulative duration of treatment

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Registry information

Acronym: PPP-Care

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Jan 19, 2022
Registry last updated
Jun 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.